AtriCure Inc. announced that the first patient was enrolled and treated at PinnacleHealth Hospitals in Harrisburg, Pa., in the ATLAS clinical study. This observational study explores the use of the AtriClip device to decrease complications associated with post-operative atrial fibrillation (POAF) by targeting specific cardiac surgery patient populations at the highest risk of developing POAF.

Laerdal Medical, provider of simulation solutions for healthcare, and SonoSim Inc., provider of ultrasound education and training, announced the commercial release of the Laerdal-SonoSim Ultrasound Solution for SimMan3G and SimMom.

The Centers for Medicare & Medicaid Services (CMS) and America’s Health Insurance Plans (AHIP), as part of a broad Core Quality Measures Collaborative of healthcare system participants, released seven sets of clinical quality measures. These measures support multi-payer alignment, for the first time, on core measures primarily for physician quality programs. This work is informing CMS’s implementation of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) through its measure development plan and required rulemaking.

Increasingly patients and providers are interested in using remote monitoring devices to help with their healthcare. Researchers at the University of California Los Angeles (UCLA) sought to determine if these devices could be useful in preventing 180-day all-cause hospital readmissions for heart failure patients.

Biotronik announced a partnership with Maquet Medical Systems USA to distribute Biotronik peripheral vascular devices in the United States.

St. Jude Medical Inc. announced U.S. Food and Drug Administration (FDA) approval of the first-to-market MultiPoint Pacing technology featured on the Quadra line of cardiac resynchronization therapy defibrillators (CRT-D) and pacemakers.

February 17, 2016 — Up to 10 percent of people with high blood pressure have resistant hypertension — high blood pressure that remains elevated despite treatment with at least three blood pressure medications.

viosworks, cardiac MRI
Philips, ScanWise, MR conditional

For decades now, magnetic resonance imaging (MRI) has been noted for its excellent soft tissue imaging capability with zero radiation dose. It has been called the imaging modality of the future over and over, but due to its complexity, long exam times and high cost, its growth has been severely limited. This especially has been the case for cardiac MRI, which only accounts for about 1 percent of all MRI exams in the United States. However, new technologies introduced at the 2015 Radiological Society of North America (RSNA) meeting in December may encourage future expansion. 
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now